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1. Introduction 
Anthracyclines are among the most utilised antitumour drugs ever developed. The 
discovery of one of the leading compounds, doxorubicin (DOX) in early 1960s was a major 
advance in the fight against cancer. According to the WHO, it belongs to the group of 17 
essential drugs that are used to treat curable cancers or cancers for which the cost-benefit 
ratio clearly favours drug treatment (Sikora et al., 1999). It is used, often with other 
antineoplastic, in the treatment of Hodgkin's disease, non-Hodgkin's lymphomas, acute 
leukaemias, bone and soft-tissue sarcoma, neuroblastoma, Wilm's tumour, and malignant 
neoplasms of the bladder, breast, lung, ovary, and stomach. The mechanisms of cytotoxicity 
of DOX in cancer cells is complex including: inhibition of both DNA replication and RNA 
transcription; free radicals generation, leading to DNA damage or lipid peroxidation; DNA 
cross-linking; DNA alkylation; direct membrane damage due to lipid oxidation and 
inhibition of topoisomerase II (Gewirtz, 1999; Minotti et al., 2004). Today, topoisomarase II is 
generally recognized to be the cellular target of DOX, which act by stabilizing a reaction 
intermediate in which DNA strands are cut and covalently linked to this enzyme (Simunek 
et al., 2009). It blocks subsequent DNA resealing. Failure to relax the supercoiled DNA 
blocks DNA replication and transcription. Furthermore, DNA strand breaks may trigger 
apoptosis of cancer cells. However, as with all traditional antineoplastic drugs, DOX 
administration is accompanied by adverse drug reactions arising from the limited selectivity 
of their anticancer action (Aronson et al., 2006; McEvoy et al., 2010). Particularly common 
are bone marrow depression, which may be dose-limiting. White cell count reaches a nadir 
10 to 15 days after a dose and usually recovers by about 21 days. Gastrointestinal 
disturbances include moderate or sometimes severe nausea and vomiting; stomatitis and 
oesophagitis may progress to ulceration. Alopecia occurs in the majority of patients. 
Occasional hypersensitivity reactions may also occur. However, a cumulative-dose 
dependent cardiac toxicity has been a major limitation of DOX use. 
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2. Doxorubicin-induced cardiotoxicity 
Cardiac toxic effects were first documented during early clinical evaluations of DOX, and in 
the late 1970s, first retrospective clinical studies showed convincingly that the observed 
cardiac disturbances could be directly attributable to repeated DOX administration. At the 
same time, these studies established the cumulative DOX dose received as the main risk 
factor of cardiotoxicity (Green et al., 2001; Lefrak et al., 1973; Von Hoff et al., 1979). 
Considering that more than 50% of long term-survivors of childhood cancer alone were 
treated with DOX or another anthracycline, anthracycline-induced cardiotoxicity is a widely 
prevalent problem that cannot be ignored. Namely, long-term survivors of childhood cancer 
are 8 times more likely than the general population to die from cardiovascular-related 
disease and, compared to sibling controls, they are 15 times as likely to suffer from heart 
failure (HF)(Lipshultz & Adams, 2010; Lipshultz et al., 1991). Despite very large numbers of 
new anthracycline compounds synthesized and tested, only few ones have been approved 
for clinical use, and none of them has fulfilled expectations of substantially improved 
cardiac safety. Therefore, a growing need to develop effective and cardioprotective 
strategies remains, in order to find a balance between the risks of cardiotoxicity and the  
benefits of oncologic therapy with DOX. 
2.1 Clinical presentation and risk factors of doxorubicin-induced cardiotoxicity 
DOX-induced cardiotoxicity is most often divided into 3 categories: acute changes, early-
onset chronic progressive cardiotoxicity and late-onset chronic progressive cardiotoxicity 
(Aronson et al., 2006; Schimmel et al., 2004; Wouters et al., 2005) Acute DOX-induced 
cardiotoxicity occurs during DOX administration or immediately afterwards. It typically 
involves transient electrocardiographic abnormalities such as non-specific ST-T changes and 
QT prolongation, vasodilatation and hypotension. Pericarditis-myocarditis syndrome and 
ventricular dysfunction which manifest 1 to 3 days after the DOX treatment are extremely 
rare, and were more frequently seen in early trials using very high doses of DOX. Most 
often, all of the disturbances attenuate after discontinuation of the therapy. Early-onset 
chronic cardiotoxicity, such as cardiomyopathy which progresses to congestive heart failure 
(CHF) usually occurs within 1 year after discontinuance of DOX therapy. CHF may occur as 
total cumulative dosage of DOX approaches or exceeds 550 mg/m2. Chronic cardiotoxicity 
reflects a progressive injury and loss of cardiac myocytes, with increasing cumulative DOX 
dose resulting in thinning of ventricular wall and decreased systolic performance. It is 
characterised by dilated (less often restrictive, mostly in children) cardiomyopathy, with 
subsequent development of left ventricular contractile dysfunction and congestive heart 
failure. Histopathological changes are quite unique and consist of distension of the 
sarcoplasmic reticulum of myocytes, cytoplasmic vacuolization, swelling of mitochondria 
and myofibrillar disarray and loss (Ferrans et al., 1997). Symptoms of the CHF include 
tachycardia, tachypnea, dilatation of the heart, exercise intolerance, pulmonary oedema, 
peripheral oedema and needs for treatment with diuretics and cardiac glycosides. These 
manifestations may respond to cardiac supportive therapy and may be self limiting, or may 
be irreversible and unresponsive to therapy and fatal  (Aronson et al., 2006; Singal & 
Iliskovic, 1998; Sweetman, 2011; Wouters et al., 2005). Finally, late-onset chronic progressive 
DOX-induced cardiotoxicity occurs at least 1 year after the completion of therapy, 
sometimes even after decades of a prolonged asymptomatic interval. It has been suggested 
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that myocyte damage and ventricular dysfunction progress after the initial myocardial 
insult and may lead to late-onset cardiac decompensation. Although the  DOX dose of 550 
mg/m2  was suggested to be relatively safe, CHF was found to begin at a lower cumulative 
dose in the presence of other risk factors, such as age above 70 years, combination therapy 
(cyclophosphamide, dacarbazine etc.), previous or concomitant mediastinal radiotherapy, 
history of pre-existing cardiac disease, or liver disease (Ludke et al., 2009; Singal & Iliskovic, 
1998; Sweetman, 2011). Although sensitivity to DOX-induced cardiotoxicity exhibit large 
interindividual variation, the risk of developing  impairment in myocardial function 
increases with increasing cumulative dose, occurring in 3-5, 5-8, and 6-20% in those 
receiving cumulative doses of 400, 450, or 500 mg/m2, respectively, in schedules of rapid IV 
doses given every 3 weeks. The strong association between cumulative DOX dose and 
cardiotoxicity obviously is more important with increasing time after treatment (Lipshultz & 
Adams, 2010). Some clinicians suggest that late-onset cardiotoxicity can be clinically 
manifest in response to stressful situations (e.g. surgery, pregnancy), exercise and viral 
infection. Late-onset doxorubicin toxicity can be expected to be observed more frequently 
with the growing number of long-time survivors (survivors of childhood cancers) who have 
received DOX. Long term follow up shows that overt cardiac failure occurs from 0 to 16% of 
patients receiving anthracycline therapy. It depends on the cumulative dose, well 
recognized risk factor for late cardiotoxicity, radiation therapy involving the heart, age at 
diagnosis, greater length of follow up, higher dose rate and previous exposure to 
anthracycline (Kremer et al., 2002; McEvoy et al., 2010; Wouters et al., 2005). Therefore, 
recommendations for screening and management of late effects of therapeutic exposure 
used during treatment for pediatric malignancies are very important in every day practice.  
2.2 Monitoring and markers of doxorubicin-induced cardiotoxicity 
Clinical manifestations found on physical examination, and/or changes found on 
electrocardiographic (ECG) monitoring are not specific enough to diagnose DOX-induced 
cardiotoxicity. However, a persistent reduction in the voltage of the QRS wave is generally 
indicative of the need to perform further tests. Non-invasive cardiac monitoring, by means 
of serial echocardiography studies or radionuclide angiography, is useful in predicting the 
development of cardiomyopathy. However, since it may give normal results until damage is 
quite advanced, sensitivity may be improved with exercise stress tests (Singal & Iliskovic, 
1998; Steinherz et al., 1992). Endomyocardial biopsy is the most sensitive indicator of 
cardiomyopathy, but it is limited by its invasiveness, need for histologic expertise, and costs. 
Therefore, there is need for simple methods, like serum and plasma markers to identify 
patients at risk. There is some preliminary evidence to suggest that concentrations of cardiac 
troponins and natriuretic peptides could be used as predictive markers of myocardial 
damage (Ludke et al., 2009; Schimmel et al., 2004). Anyway, according to the Childrens' 
Cancer Study Group (Steinherz et al., 1992), standard echocardiogram should be performed 
before the beginning of the treatment and at the third, sixth and 12th month after its 
completion. Subsequent exam should be repeated every 2 years for the rest of the life. 
2.3 Prognosis and treatment 
Historically, DOX-induced cardiomyopathies have a poor prognosis and mortality rate as 
high as 61% (Allen, 1992; Von Hoff et al., 1979; Wouters et al., 2005). It is refractory to 
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conventional therapy, therefore cardiac transplantation is the only solution associated with 
improved survival (Aronson et al., 2006; Sweetman, 2011). Just recent study reports that the 
response of DOX-induced cardiomyopathy to the current standard medical therapy is 
better, especially in patients treated with β-blockers. Nowadays, in the treatment of CHF, 
including DOX-induced cardiomyopathy, β-blockers and angiotensin-converting enzyme 
(ACE)  inhibitors, are proven Class I medications according to the American College of 
Cardiology/American Heart Association and Canadian Cardiovascular Society guidelines 
(Hunt, 2005; Malcom et al., 2008). 
2.4 Mechanisms of doxorubicin induced cardiac Injury 
Two important characteristics of doxorubicin induced cardiomyopathy are that is dose 
dependent and it is refractory to the commonly used therapeutic procedures (Lefrak et al., 
1973; Singal & Iliskovic, 1998). Pathogenesis of cardiac injury caused by doxorubicin is 
multifactorial and it is in direct relationship with metabolism and antitumor activity of the 
drug (Figure. 1). Free radical stress, calcium overloading and mitochondrial dysfunction are 
main triggers in doxorubicin-induced cardiotoxicity. Subsequent gene expression changes 
and activation of the ubiquitin-proteasome system, cell death, as well as innate immunity 
activation all contribute to the toxicity (Shi et al., 2011). The level of the doxorubicin-induced 
oxidative stress is up to 10 times greater in the heart than in the other tissues (liver, kidney, 
spleen) (Davies & Doroshow, 1986; Doroshow & Davies, 1986; Gaetani et al., 1989; 
Lenzhofer et al., 1983; Milei et al., 1986; Mukherjee et al., 2003; Siveski-Iliskovic et al., 1995), 
and therefore oxidative injury of the heart is widely accepted theory presumed as a primary 
mechanism of the DOX-induced cardiotoxicity. 
2.4.1 Role of iron and free radicals 
Although doxorubicin-induced cardiotoxicity is multifactorial, formation of reactive oxygen 
species (ROS) has a leading role in promoting the oxidative myocardial damage. The high 
level of oxidative stress generated by anthracyclines is accounted to the molecular 
characteristics which allows drug to easily undergo redox reaction and subsequently free 
radical cascade.  
Doxorubicin is belonging to the group of anthracycline antibiotics consist of 
naphthacenequinone nucleus linked through a glycosidic bond to an amino sugar, 
daunosamine (Figure. 2a). One-electron addition to the quinone moiety in ring C of DOX 
result in formation of a semiquinone that quickly regenerates its parent quinone by reducing 
oxygen to reactive oxygen species, like superoxide anion radical (O2-) and hydrogen 
peroxide (H2O2) (Figure. 2b).  
This futile cycle is supported by a number of NAD(P)H-oxidoreductases [cytochrome P450 
or -b5 reductases, mitochondrial NADH dehydrogenase, xanthine dehydrogenase, 
endothelial nitric oxide synthase (reductase domain) (Halliwell & Gutteridge, 2007; Minotti 
et al., 1999; Vasquez-Vivar et al., 1997). The dismutation of the O2.- is catalyzed by 
superoxide dismutase enzyme or it may occur spontaneously in the acidic environment -
(pH<7). Hydrogen peroxide is low toxic molecule, which is eliminated from the body by 
enzymatic antioxidative defence system (catalase -CAT and glutathione peroxidase - GPx). 
However, in the presence of the transition metals, especially iron, H2O2 and O2- can  
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Fig. 1. A summary of potential mechanisms involved in doxorubicin (Dox)-induced 
cardiomyopathy as described in the text. The major mechanisms involve ROS and iron (red). 
Meanwhile, Dox-induced cell death (necrosis, apoptosis, and autophagy) and activation of 
innate immunity (brown), gene changes that reduce cardiac-specific gene expression or 
trigger apoptosis, induction of cardiac premature senescence in cardiomyocytes (yellow), 
activation of the ubiquitin-proteasome system (UPS) causing the balance of the protein 
system to shift toward pro-apoptosis, downregulation of prosurvival gene (NRG1 and ErB4) 
expression (blue), and impaired cardiac repair by inhibiting bone marrow, cardiac 
progenitor cell, and/or endothelial cell function (green) all emerge as potential mechanisms 
contributing to Dox cardiotoxicity. ROS reactive oxygen species, IRP iron regulatory protein, 
TLR toll-like receptor, TIR toll-interleukin-1 receptor, CARP cardiac Adriamycin-responsive 
protein, H-FABP heart fatty acid binding protein, OCTN organic cation/carnitine 
transporter, ARC apoptosis repressor with caspase recruitment domain, NFAT nuclear 
factors of activated T-cell, TauT taurine transporter, NRG neuregulin, ErbB epidermal 
growth factor receptor B, BMPC bone marrow cardiac progenitor cell, CPC cardiac 
progenitor cell, EC endothelial cell, arrows pointing up or down (inside text boxes) indicate 
increases or decreases in function or expression, horizontal arrows indicate positive 
regulatory sequence, blocks represent inhibition (Shi et al., 2011). 
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Fig. 2. Doxorubicin mediated redox cycling and free radical production 
 
a) 
b) 
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generate highly toxic hydroxyl radical (OH). This process is occurring during the Haber-
Weiss reaction (1) which is actually quite slow. Presence of iron strongly catalyzes formation 
of OH, in two step process. In the first step ferric ion (Fe3+) is reduced in to ferrous ion 
(Fe2+) by O2- (2). Ferrous ion than reacts with hydrogen peroxide (generated during DOX 
reduction) resulting with formation of hydroxyl radicals (Fenton reaction) (3). 
Unlike hydrogen peroxide and superoxide anion radical, hydroxyl radical is extremely 
reactive and cannot be neutralized by antioxidative enzymes. Instead, OH reacts with 
polyunsaturated fatty acids forming lipid peroxides, conjugated dienes and malonyl 
dialdeyde. As a consequence, the structure of lipid bilayer is modified resulting in cell 
membrane damage followed by cell dysfunction. In addition ROS can seriously affected 
proteins and nucleic acids, particularly ion channels and ion transporters (Halliwell & 
Gutteridge, 2007). Zhu et al. proved involvement of ROS in apoptosis in cardiac myocytes 
through p38 MAP kinase which is inhibited by CAT and SOD scavengers (Zhu et al., 1999). 
Cells have very little or no free iron available for catalyzing free radical reactions. However, 
studies have shown that redox cycling of doxorubicin directly increases the intracellular 
iron pool (Minotti et al., 1999; Xu et al., 2005; Xu et al., 2008). Formation of DOX 
semiquinone followed by O2- generation is accompanied by iron releasing from ferritine. 
Ferritines are sphere shaped complex of 24 protein subunits with central cavity which can 
store up to 4500 atoms of iron. Eight channels through the sphere are lined by hydrophilic 
amino acid residues and six more are lined by hydrophobic residues. These transprotein 
channels provide the route for iron entry and exit from ferritin shell (Harrison et al., 1986; 
Theil, 1987). Anthracycline semiquinone is too large for entering the ferritin. However, 
superoxide anion is small enough to penetrate the shell and has reduction potential lower 
than that of polynuclear ferric oxohydroxide stored in the ferritin core. Combination of 
steric and thermodynamic factors thus enables O2- to reach and reduce the iron pool of 
ferritin promoting the release of iron in its Fe(II) form through transprotein channels 
(Minotti, 1993; Minotti et al., 1999).  
Furthermore, intracellular iron enrichment is mediated by doxorubicin and its metabolites. 
Cellular iron homeostasis is regulated by transferring receptor (TfR) and ferritin. Both TfR 
and ferritin are mainly regulated at a post-transcriptional level involving interactions of iron 
regulatory protein (IRP-1) and iron responsive elements (IRE) in target genes (Xu et al., 2005; 
Xu et al., 2008). Namely, DOX can disrupt the Fe-S cluster of cytoplasmatic aconitase and 
inhibit IRP-1 whose role is to adapt levels of cellular iron according to metabolic needs. 
The second mechanism by which Fe promotes oxidative injury involves generation of 
doxorubicin-iron complexes (DOX-Fe). Anthracyclines chelate Fe(III) forming the 1:1, 2:1 or 
3:1  iron complex with association constant of 1033 (Figure. 2b) (Beraldo et al., 1985; May et 
al., 1980). In the presence of reducing agents (as NADPH cytochrome P450 reductase, 
glutathione or cysteine) DOX-Fe (III) complex are converting into DOX-Fe (II). This reaction 
come along with the formation of O2-and conversion of quinone form of DOX to 
semiquinone free radical. Products of this reaction are further involving in the iron 
catalyzed Haber-Weiss reaction resulting in production of highly aggressive hydroxyl 
radicals (eq. 1-3). The semiquinone radical can be transform into C7 deoxydaglicone which 
is the potent alkylating agent. 
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Fig. 3. Hypothesized mechanism of chronic cardiotoxicity mediated by DOXol and/or DOX-
Fe complex 
Different pathway of doxorubicin toxicity, other than oxidative injury, is involved in cardiac 
toxicity of the drug. Doxorubicinol (DOXol) is hydroxy metabolite of DOX formed upon two 
electron reduction on the C-13 carbonyl group of doxorubicin (Figure. 3). This reaction is 
catalyzed by NADPH dependent carbonyl reducatses (Forrest et al., 1991). DOXol is redox 
inactive and therefore not involved in free radical production. Notwithstanding, DOXol is 
involved in iron homeostasis (Licata et al., 2000; Minotti et al., 2001), myocardial energy 
metabolism, ionic gradients and calcium movements, impairing cardiac contraction and 
relaxation (Boucek et al., 1987; Olson, R. D. et al., 1988). Moreover, conversation of 
doxorubicin into DOXol significantly increases polarity of the parent drug molecule, thus 
favouring its retention within the cell. Considering the all aforesaid mechanisms of DOXol 
acting, it is logical conclusion that alcohol metabolite of doxorubicin is most likely 
responsible for the DOX induced chronic cardiomyopathy (Figure. 3), while iron mediated 
free radical injury promote acute cardiotoxicity This hypothesis is supported by findings of 
Miranda and co-workers which found that patients harbouring gene mutations in 
hereditary hemochromatosis show increased susceptibility to doxorubicin cardiotoxicity 
and exacerbated iron metabolism (Miranda et al., 2003). Numerous studies on transgenic 
mice with overexpressed antioxidants like catalase (Kang et al., 1996), superoxide dismutase 
(Abou El Hassan et al., 2003; Loch et al., 2009; Yen et al., 1996) and metallothionene (Kang, 
1999; Kang et al., 1997; Merten et al., 2005; Sun & Kang, 2002; Sun et al., 2001) have shown 
beneficial against DOX induced cardiotoxicity, confirming strong involvement of free 
radicals in oxidative injury of the heart.  
The high oxidative metabolism and the poor antioxidative defence, compared with other 
organs, most likely explains why the doxorubicin is selectively toxic to the heart. Compared 
www.intechopen.com
Doxorubicin-Induced Oxidative Injury  
of Cardiomyocytes – Do We Have Right Strategies for Prevention? 
 
97 
to the liver, the cardiac antioxidant defense system is moderate. There is 150 times less catalase 
and four times less superoxide dismutase in the heart (Doroshow & Davies, 1986; Doroshow et 
al., 1980). In addition, the unique structure of cardiomyocytes, in which 50% of the cell 
organelles are mitochondria, serving both as a source and target for ROS, may explain why 
anthracycline antibiotics are selectively toxic to the heart (Berthiaume & Wallace, 2007). 
Cardiac mitochondria possess a NADH dehydrogenase on the outer surface of the inner 
mitochondrial membrane. Reduction of an anthracycline to the corresponding semiquinone by 
this enzyme produces an extremely high level of oxidative stress because the anthracycline 
transfers an electron to molecular oxygen and forms superoxide radicals. In relation to 
oxidative reactions, it must be emphasized that doxorubicin  possess high affinity for 
cardiolipin, cardiospecific phospholipid that is reach in polyunsaturated fatty acids also placed 
in inner mitochondrial membrane. This high affinity, besides accumulation of DOX in interior 
of cardiomyocytes, also enables formation of DOX-cardiolipin complexes which can act as the 
substrate for the initiation of lipid peroxidation (Goormaghtigh & Ruysschaert, 1984). Once 
initiated, peroxidation continues autocatalytically, and has a progressive course that results in 
structural and functional changes in the heart tissue. The ultimate damage to mitochondria is 
oxidative damage of the mitochondrial DNA, which interferes with the regenerative capacity 
of the organelle. Once this irreversible damage occurs, the cardiomyocytes are destined to 
undergo apoptosis or necrosis, an event that may not occur until months or years after 
chemotherapy is completed (Davies & Doroshow, 1986; Doroshow et al., 1980). Therefore, the 
most significant pathological changes appear in the heart. 
It is evident that there are still unknowns about exact mechanisms of the toxic effects of 
doxorubicin and its metabolites. In spite numerous investigations at the molecular level, 
iron mediated free radical injury and alteration in intracellular iron homeostasis have a key 
role in cardiotoxicity of anthracycline antibiotics and therefore considered classical 
mechanism underlying cardiac impairment induced by DOX.  
2.5 Strategies for cardioprotection 
Today's oncologists must be fully aware of cardiovascular risks to avoid or prevent adverse 
cardiovascular effects. The primary goal in the prevention is to minimise cardiac toxicities 
and to maximise oncological efficacy (Dorr, 1991; Schimmel et al., 2004). Currently, several 
preventive measures, such as: limiting cumulative dose of DOX, altering its administration, 
using new anthracycline analogues; combination with protective drugs and nutritional 
supplements are used.  
2.5.1 Limiting cumulative dose of doxorubicin 
Before the association between higher cumulative dose of DOX and the greater risk of 
cardiotoxicity was established, cumulative DOX doses greater than 400 mg/m2 were 
administered to children with acute lymphoblastic leukaemia (ALL). Unfortunately, 
progressive cardiotoxic effects, clinically important, continued years after the DOX 
treatment completion (Lipshultz et al., 1991; Lipshultz et al., 2005). As a result, cumulative 
doses of DOX given to high-risk children and adolescent with ALL were reduced to a 
cumulative dose no more than 360 mg/m2.. Later on, after median follow up of 8.1 year, on 
the basis of obtained results, the cumulative DOX dose for high-risk ALL patients were 
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further reduced to 300  mg/m2  (Nysom et al., 1998). However, patients vary widely in 
sensitivity and these values represent relatively arbitrary choices on a continuum of risk: 
there is no single safe dose (Shan et al., 1996; Von Hoff et al., 1979). Studies of late-onset 
anthracycline cardiotoxicity in childhood cancer survivors indicate that doses of DOX as low 
as 100 mg/m2 increase the risk of reduced fractional shortening and higher afterload, 
whereas a cumulative dose of 270 mg/m2  increases the risk of such abnormalities 4.5-fold. 
Even at doses that produce no symptoms, subclinical myocardial damage may occur, and in 
children this may result in diminished cardiac reserve and heart disease in later life (Hale & 
Lewis, 1994; Lipshultz et al., 1991).  
2.5.2 Altering doxorubicin administration   
Alteration of the dosage schedule to weekly rather than three-weekly dosage, or the use of 
continuous infusion, has also been advocated as a way of reducing doxorubicin 
cardiotoxicity (Legha et al., 1982a; Lum et al., 1985; Torti et al., 1983). At the same time, it 
was believed that continuous infusion might provide some cardioprotective benefits, 
because long-term exposures to drugs at modest concentrations would be safer than a 
pulsed supply of the drug at higher concentrations. Therefore, it was incorporated in many 
pediatric protocols although the comparative efficacy of these dosage schedules in various 
cancers and long-term effects on the development of DOX-induced cardiotoxicity have not 
been established tz (Lipshultz et al., 2005; Lipshultz et al., 2010). However, recently 
published  meta-analysis performed to clarify the risk of early and late cardiotoxicity of 
anthracycline agents in patients treated for breast or ovarian cancer, lymphoma, myeloma or 
sarcoma showed that DOX given as bolus significantly increased the risk of clinical and 
subclinical cardiotoxicity compared with continuous infusion.  
2.5.3 Use of doxorubicin-analogues   
Several anthracycline derivatives have been developed with the aim of reducing the 
inherent cardiotoxicity of this class of compounds, including esorubicin, quelamycin, 
rodorubicin, and detorubicin. However, although this strategy has had some success, it 
turned out that almost all these compounds exhibit some degree of cardiotoxicity (Aronson 
et al., 2006; Sweetman, 2011; Weiss, 1992; Wouters et al., 2005). Epirubicin, idarubicin and 
mitoxantrone are the most promising ones. In the recently performed meta-analysis 
epirubicin significantly decreased the risk of clinical cardiotoxicity OR 0.39 (0.16, 0.57; 
p0.008; I2  0.5%), as well as any cardiotoxic event compared with DOX (Smith et al., 2010). 
2.5.4 New drug-delivery systems and doxorubicin application 
A promising approach to increase the efficacy and decrease the side-effects of DOX is its 
binding to drug delivery system, such as liposomes, nanoparticles and different cancer-
targeting systems. Among the structural modifications of DOX, the liposome-encapsulated, 
is the one of the most promising cardioprotectants (Ludke et al., 2009). Liposomes are 
preferentially taken up by tissues enriched in phagocytic reticuloendothelial cells and with a 
sinusoidal capillary system like the liver and spleen. The continuous capillaries containing 
tissues, like heart muscle hardly take up liposomes, but it is not the case with the leaky 
capillary system of tumor site. Thus, the changes in tissue distribution of liposomal DOX 
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lead to less drug exposure in sensitive organs. The ability to reduce the plasma levels of free 
DOX is probably the source of the reduced cardiotoxicity provided by its liposomal 
formulation (Fulbright et al., 2010). Also, the release of drug is slow, which may avoid high 
peak plasma concentrations. It exists both in pegylated lyposomal and, at the moment, these 
two formulations are approved for clinical use by the US Food and Drug Administration 
(Ludke et al., 2009; Sweetman, 2011). Several randomized clinical trial in adults have 
examined the activity and cardiotoxicity of liposomal DOX. Most of them indicated that the 
activity of liposomal DOX is similar to that of conventional, whether given alone or in 
combination with other drugs. At the same time, the risk of cardiotoxicity is markedly lower 
with liposomal DOX (Gianni et al., 2008; McEvoy et al., 2010; Safra, 2003; Smith et al., 2010). 
However, although clinically approved, conventional DOX continues to be the major drug 
in antineoplastic combinations used in the management of most solid tumors. Nanoparticles 
made of biodegradable polymers are particles with sizes in range from 20 to 200 nm that can 
encapsulate hydrophilic or hydrophobic drugs. Drugs delivered by nanotechnology 
delivery systems have a prolonged time in the circulation (Ferrari, 2005). Although carbon 
nanotubes and gold nanoparticles have demonstrated potential as a new drug delivery 
system, clinical use has been restricted due to concerns regarding their biodegradability (Liu 
et al., 2008). These particles should link with tumor-targeting ligands, such as peptides and 
small molecules. At the moment, DOX nanoparticles shows great promise in improving the 
oral bioavailability and reducing cardiotoxicity, but so many issues wait to be resolved in 
the future (Kalaria et al., 2009).   
2.5.5 Combination with protective drugs 
Apart from cumulative dose limitations, several attempts have been made to develop 
chemoprotectants to prevent the cardiotoxicity of DOX, without attenuating its antitumor 
effect. Following the aforementioned free radical hypothesis, antioxidants used as free 
radical scavengers have been examined both in experiments, and in clinical trials. On the 
other hand, considering a very important role of iron and the DOX-iron complex, iron 
chelators have also been used for prevention of DOX-induced cardiotoxicity (Dorr, 1991; 
Links & Lewis, 1999; Simunek et al., 2009). 
3. Dexrazoxane 
One of the most examined protectors against DOX cardiotoxicity is dexrazoxane (DEX). 
Activity of DEX against DOX-induced cardiotoxicity may be attributable to the intracellular 
conversion of DEX to an open-ring derivative ADR-925 which chelates iron, since one means 
of generating oxygen-free radicals may involve intramolecular reduction of DOX-iron 
conjugate. The cardioprotective activity of DEX is thought to result primarily from chelation 
of free and/or DOX-bound ferric ions in the myocardium by ADR-925 and some other 
hydrolysis products of DEX (Dorr, 1996; Hasinoff, 1989). As a result, the pool of free iron in 
the myocardium is reduced and bound iron is displaced from its potentially damaging 
complexes with DOX, thus preventing the formation of superoxide radicals after redox 
recycling. DEX has been shown experimentally to reduce DOX-induced cardiotoxicity in 
mice (Alderton et al., 1990); in rats  (Della Torre et al., 1999; Herman et al., 1994; Villani et al., 
1990); in beagle dogs (Herman et al., 1988) and in miniature swine (Herman & Ferrans, 
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1983). Treatment with DEX not only significantly reduced the incidence of cardiac lesions, 
but also increased the survival rate in animals treated with anthracyclines compared with 
anthracycline-only treated controls. Actually, DEX allowed administration of significantly 
larger cumulative doses of DOX, that otherwise would have been lethal in these animal 
models (Wiseman & Spencer, 1998). Studies in rats and beagle dogs have shown that DEX is 
generally more effective when administered shortly before or simultaneously with, rather 
than after DOX. In randomized, controlled trials, DEX provided effective cardioprotection in 
both adults and children receiving DOX chemotherapy for various malignancies (Lipshultz 
et al., 2004; Lopez et al., 1998; Speyer et al., 1992; Swain et al., 1997; Venturini et al., 1996; 
Wexler et al., 1996). In recent meta – analysis, data on clinical heart failure from eight trials 
with a total of 1561 patients were collected (van Dalen et al., 2011a). There were 11 cases of 
clinical heart failure among 769 patients randomised to DEX and 69 among 792 randomised 
to the control group. The meta-analysis showed a benefit in favour of DEX use (RR 0.18, 95% 
CI 0.10 to 0.32, P < 0.00001). In another 6 randomized clinical trials which evaluated 
cardioprotective agent DEX, four on women with advanced breast cancer, one with young 
people with sarcoma and one with  breast cancer or sarcoma DEX given with DOX 
significantly reduced the risk of clinical cardiotoxicity, subclinical cardiotoxicity and any 
cardiotoxic event compared with DOX with no cardioprotective agent (Smith et al., 2010). 
Data on response rate (defined as the number of patients in complete and partial remission) 
could be extracted from six trials with a total of 1021 patients. These trials used comparable 
criteria to assess tumour response. There were 223 complete and partial responses among 
503 patients randomised to DEX and 260 among 518 randomised to the control group. Meta-
analysis showed no significant difference between the treatment groups. However, an 
important question regarding any cardioprotective intervention during DOX therapy is 
whether the cardioprotective drug could decrease the heart damage by anthracyclines 
without reducing the anti-tumour efficacy and without negative effects on toxicities other 
than cardiac damage. At the moment, despite its clear cardioprotective effects, DEX is not 
routinely used in clinical practice. This might be explained by the suspicion of interference 
with anti-tumour efficacy (that is response rate and survival) and by the occurrence of 
secondary malignant disease. However, meta-analyses of DOX anti-tumour efficacy and the 
appearance of secondary malignant diseases showed no significant difference between 
patients who were treated with or without DEX (van Dalen et al., 2011a). This latter finding 
was also identified in a recent publication (van Dalen et al., 2011b). A meta-analysis 
including three of the four randomised trials available on secondary malignancies after 
DEX, did not show a significant difference in the occurrence of secondary malignancies 
between children treated with or without DEX (RR 1.16, 95% CI 0.06 to 22.17, P = 0.92). The 
protective effects of DEX against DOX–induced cardiotoxicity are further supported by 
studies in children with leukemias and lymphomas, as well as with other malignancies 
(Lipshultz et al., 2010; Testore et al., 2008). However, further research is needed to fully 
understand the subtle risks associated with the use of DEX, as well as which methods of 
DEX administration are most efficient, and which doses are necessary to achieve adequate 
protection in children. At the moment, DEX is the only cardioprotective agent with proven 
efficacy in cancer patients receiving DOX. DEX is approved in many countries, including the 
United States, Canada, and a number of European countries. Current guidelines support the 
use of DEX for patients with metastatic breast cancer who have received more than 300 
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mg/m2 of DOX in metastatic setting and who may benefit from continued DOX-containing 
therapy; treatment of patients who received more than 300 mg/m2 in the adjuvant setting 
should be individualized, with consideration given to the potential for DEX to decrease 
response rates as well as decreasing the risk of cardiac toxicity. It should not be used for 
patients with metastatic breast cancer receiving initial DOX-based chemotherapy (Hensley 
et al., 2009; McEvoy et al., 2010; Sweetman, 2011). There is insufficient evidence to make 
recommendation for the use of DEX in the treatment of pediatric malignancies. It can be 
considered in adult patients who have received more than 300 mg/m2 of DOX-based 
therapy for patients with advanced or metastatic cancer who have previously received 
anthracyclines. However, since DEX may potentiate haematological toxicity induced by 
chemotherapy, or the results for these adverse effects are ambiguous, for each individual 
patient a physician should balance the cardioprotective effects of DEX against the possible 
risk of adverse side effects (Ludke et al., 2009; van Dalen et al., 2011a). In addition, DEX 
appears equally well tolerated when administered with DOX at either 10:1 or 20:1 dosage 
ratios (e.g. if 50 mg/m2 of DOX is used, 500 mg/m2 DEX should be given). A reconstituted 
DEX solution should be given intravenously by slow push or rapid-drip infusion from a 
bag, starting 15-30 minutes before DOX administration. The optimal treatment regimen and 
cost effectiveness of DEX, and its protective efficacy against late-onset cardiotoxicity in 
patients given DOX chemotherapy during childhood or adolescence, are yet to be 
determined (Cvetkovic & Scott, 2005). On  September 6, 2007, the U.S. Food and Drug 
Administration approved Totect 500 mg, (dexrazoxane hydrochloride for injection) for the 
treatment of extravasation resulting from i.v. anthracycline therapy, an uncommon but 
serious complication (Kane et al., 2008). From all these facts,  it can be concluded that well-
designed cardioprotective intervention, like usage of DEX, can be an effective option as a 
strategy for DOX-induced cardiotoxicity prevention. Moreover, our ability to develop drugs 
such as DEX depends on our understanding of the molecular mechanisms involved in both 
antineoplastic and cardiotoxic effects of DOX. As it has been already mentioned, the current 
prevailing hypothesis is that DEX exerts its cardioprotective effects by binding free Fe, 
loosely bound Fe and Fe complexed to DOX,  thus enabling the prevention of site-specific 
oxygen radicals production that damages cellular components of the heart (Cvetkovic & 
Scott, 2005; Dorr, 1996; Hasinoff, 1989). However, none of the other Fe chelating agents 
examined (aroylhydrazone iron chelators, defepirone etc) has reached the high protective 
efficacy of DEX. On the other hand, ADR-925 has a lower affinity for Fe than other helators, 
so it can be concluded that the iron-chelating properties of a compound are not the main 
determinants of cardioprotective action (Kaiserova et al., 2007). In recent experimental study 
it was clearly shown that DEX exerted protective effect against chronic daunorubicin 
cardiotoxicity in vivo (rabbits). Its cardioprotectiveness was based on the rescue of 
cardiomyocytes not only from  degenerative changes and non-programmed cell death, but 
also from programmed cell death (apoptosis), as well (Popelova et al., 2009). Actually, DEX 
was shown to block all the major apoptotic pathways, and, therefore, protection of 
cardiomyocytes did not seem to be primarily lipoperoxidation-dependent. Apart from all 
the aforementioned, it is already known that DEX binds directly to topoisomerase II and 
locks the enzyme in a stable and closed clamp conformation around DNA (Roca et al., 1994). 
Since, anthracyclines are, as already mentioned, topoisomerase II inhibitor, it has been 
proposed that DEX may have protective effects against such agents in this way (Lyu et al., 
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2007). In addition, beta isoform of topoisomerase II is abundant in post-mitotic myocardium, 
including mitochondria (Wallace, 2007; Wang, 2002). It was also previously mentioned that 
DOX impairs calcium homeostasis in cardiomyocytes, not only affecting sarcoplasmic 
reticulum function, but also mitochondria (Minotti et al., 2004). The fact that anthracycline-
induced calcium overload can be prevented with DEX, co-treatment gives one more 
explanation for its cardioprotective efficacy (Simunek et al., 2005). Namely,  it was shown 
that  systolic heart failure induced by chronic daunorubicin administration is primarily 
accompanied by persistent calcium overload of cardiac tissue and the protective action of 
DEX is associated with the restoration of normal myocardial Ca2 content. Therefore, 
mechanisms other than the traditionally accepted “ROS and iron” hypothesis are involved 
in DOX-induced cardiotoxicity, and knowledge of them may be a better basis for designing 
approaches to achieve efficient and safe cardioprotection.  
4. Amifostine 
Amifostine is a simple aminothiol compound that is a product of a developmental program 
initiated in 1959 by the United States Army, in studies conducted at the Walter Reed 
Institute of Research to identify and synthesize drugs capable of conferring protection to 
individuals working in radioactive environments (Dragojevic-Simic & Dobric, 1996; van der 
Vijgh & Peters, 1994). As a result of this program, over 4,000 compounds were synthesized 
and tested. Amifostine, code named WR-2721, emerged as the lead compound. The drug 
was modeled after experimental studies, which showed reduced bone marrow toxicity 
when the sulfur-containing amino acid cysteine was administered before total body 
irradiation. It was the first cytoprotective agent to be identified as being capable of 
differentially protecting nonmalignant (normal) versus malignant cells from the cytotoxic 
effects of ionizing radiation and some antineoplastic agents (Yuhas, 1979; Yuhas et al., 1980; 
Yuhas & Storer, 1969). Amifostine itself is an organic phosphorothioate that is inactive until 
it is dephosporylated by alkaline phosphatase to yeald the active free thiol (SH) form, code 
named WR-1065 (Yuhas, 1980). Selectivity, in terms of cytoprotection of normal tissue, 
preferentially, is believed to be related to differential distribution and absorbption of the 
parent drug in better perfused normal tissues as well as greater alkaline phosphatase 
acitivity in normal tissues, related to the acidic pH values found in hypoxic tumor tissues 
(Calabro-Jones et al., 1988; Dragojevic-Simic & Dobric, 1996; Smoluk et al., 1988; Utley et al., 
1984; Yuhas, 1980). Normal tissues, especially at the capillary level, have a higher specific 
activity of alkaline phosphatase which releases WR-1065 for rapid local uptake into normal 
tissues. In contrast, the activity of this enzyme in neoplastic capilaries is appreciable lower, a 
feature that contributes to this apparently selective uptake. It was also demonstrated that 
the rate constant for the uptake of WR-1065 across the cell membrane is accelerated with 
small differences in pH, favouring the pH of 7.4, which is found in normal tissues versus 
relative acidity in tumors (Calabro-Jones et al., 1988). Tissue distribution studies, performed 
in experimental animals, demonstrated the uptake of amifostine and its metabolite. Kidney, 
bladder, salivary gland and liver accumulate high level of drug; heart, small intestine and 
spleen accumulate it moderately, while the spinal cord, brain and tumours accumulate very 
little, if any (Utley et al., 1976; Washburn et al., 1976; Yuhas, 1980). The "ideal cytoprotector" 
should have: the ability to be administered before or concurrent with therapy, selectivity for  
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normal versus cancer cells, ability to prevent/reduce toxicities of chemotherapies, no 
adverse effects on therapeutic efficacy, effectiveness against a variety of therapy-associated 
toxicities, a tolerable safety profile and simple way of administration (Capizzi, 1999b; Mabro 
et al., 1999; Spencer & Goa, 1995). The aforementioned findings concerning amifostine 
prompted numerous preclinical and clinical studies and led to the ultimate marketing 
approval many years later (Hensley et al., 2009). The American Society of Clinical Oncology 
recommends amifostine for prevention of cisplatin-associated nephrotoxicity, reduction of 
grade 3 and 4 neutropenia (alternative strategies are reasonable), and to decrease acute and 
late xerostomia with fractionated radiation therapy alone for head and neck cancer. The 
current US Food and Drug Administration-approved dose of amifostine is 910 mg/m2 
intravenously over 15 minutes, 30 minutes before chemotherapy. Common toxicities include 
acute hypotension, nausea, and fatigue. When given with radiation therapy, the 
recommended amifostine dose is 200 mg/m2/day, as slow i.v. push over 3 minutes, 15 to 30 
minutes before each fraction of radiation therapy. The hypotension associated with 
amifostine at this dose is less frequent, but still requires close monitoring (Hensley et al., 
2009; McEvoy et al., 2010; Sweetman, 2011). As aforementioned, if administered before 
cytotoxic chemotherapy, amifostine provides cytoprotection of various normal tissues, with 
the exception of central nervous system, without attenuating its antitumor response 
(Capizzi, 1999a; Culy & Spencer, 2001; Dragojevic-Simic & Dobric, 1996; Kouvaris et al., 2007; 
Mabro et al., 1999; Spencer & Goa, 1995). It protects the bone marrow against both the 
harmful effects of ionizing radiation as well as cyclophosphamide, nitrogen mustard, 
melphalan, mitomicin C, carmustine, 5-fluorouracil, carboplatin and cisplatin. Protection 
from cisplatin nephrotoxicity and ototoxicity has been shown, as well as protection of 
peripheral neural tissue from cisplatin, paclitaxel, vincristine and vinblastine toxicity. 
However, data concerning amifostine efficacy in preventing the toxic effects of DOX are still 
insufficient (Bolaman et al., 2005; Dobric et al., 1998; Dragojevic-Simic et al., 2004; 
Nazeyrollas et al., 1999; Potemski et al., 2006). As previously mentioned, amifostine uptake 
has been documented to be relatively high in normal tissues compared with experimental 
tumors. Moreover, sixty minutes after amifostine injection, level in heart tissues was 
approximately sevenfold higher than in tumor and sixfold higher than in serum (Dorr, 1996; 
Yuhas, 1980). These tissue distribution studies suggest that apart from the bone marrow, 
salivary gland and kidneys, the heart might also benefit from cytoprotection provided by 
amifostine treatment prior to cardiotoxic radio- and chemotherapy. In our previous 
experiment in which general radioprotective efficacy of amifostine was examined in rats 
subjected to whole body irradiation (WBI, absolutely lethal dose of X-rays), it was shown 
that amifostine significantly protected rats and increased their survival comparing to the 
unprotected animals (Dobric et al., 2007; Trajkovic et al., 2007). Moreover, a mean cardiac 
damage (MCD) score, obtained by histopathological analysis, in amifostine-pretreated rats 
was significantly reduced compared with unprotected animals, on both days 7 and 28 after 
WBI. It has been supposed for a long time, according to data derived from the experiments 
with irradiated animals, that once inside the cell, protective effects of WR-1065 appear to be 
mediated by scavenging free radicals, hydrogen donation, induction of cellular hypoxia, the 
liberation of endogenous nonprotein sulfhydrils (mainly glutathione) from their bond with 
cell proteins, the formation of mixed disulphides to protect normal cells, etc (Brown, 1967; 
Grdina et al., 1995; Smoluk et al., 1988; Spencer & Goa, 1995). On the other hand, previous in  
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vitro studies demonstrated that amifostine, and especially WR-1065, was able to scavenge 
OH. and O2
.- , including DOX-derived O2.- generated by NADH respiration of heart 
mitochondria particles. Marzatico et al., (2000) showed that amifostine scavenging activity is 
exerted mainly against highly reactive OH. , the most dangerous reactive oxygen species 
from a biological point of view (Marzatico et al., 2000). It was also shown that both 
amifostine and WR-1065 protected cultured neonatal rat cardiac myocytes against DOX-
induced loss of cell viability  (Dorr et al., 1996). These results had clinical relevance since 
they showed that the exposure concentrations of amifostine and WR-1065 were limited to 
2.0 μg/ml, which was 10% of the peak plasma level achieved in humans given intravenous 
amifostine 740 mg/m2 (Shaw et al., 1988). Effects of amifostine on perfused isolated rat heart 
and on acute DOX-induced cardiotoxicity were also examined (Nazeyrollas et al., 1999). 
Amifostine induced coronary vazodilatation, and, when associated with cardiotoxic 
concentrations of DOX, displayed cardioprotective effects, but the mechanism of its action 
was not elucidated. Moreover, in vivo experiments demonstrated that selective 
cytoprotection against DOX-induced toxicity with amifostine and WR-1065 can be achieved 
without abrogating antitumor activity of DOX (Bhanumathi et al., 1994; Dorr, 1996; Spencer 
& Goa, 1995). In our own previous study (Dobric et al., 2003; Dragojevic-Simic et al., 2004) 
the efficacy of amifostine (75 mg/kg ip) in reducing the cardiotoxicity of DOX in Wistar rats 
given in a dose of 1.25 mg/kg ip, 4 times per week, for 4 weeks was examined. Amifostine 
was administered each time, 20 min. before DOX. Mortality, general condition and body 
weight of animals were observed, while evaluation of cardioprotective efficacy of amifostine 
was performed by analyzing the ECG parameters, response to pro-arrhythmic agent 
aconitine, as well as activity registration of the in situ rat heart preparations. The 
pretreatment with amifostine significantly reduced mortality of rats comparing with 
unprotected group and reversed the arrhythmogenic dose of aconitine to values not 
significantly different from the control ones. It also antagonized DOX depressive effects on 
heart contractility. Moreover, a MCD score, obtained by histopathological analysis, in 
amifostine-pretreated rats was significantly reduced compared with unprotected animals, 4 
weeks after the last dose of treatment. Also, amifostine significantly decreased number of 
mast cells in the heart in DOX-treated rats. Although mast cells could also be seen 
everywhere in the myocardium, they were predominantly situated around the blood vessels, 
like in control. Some other investigations in which rats were subjected to relatively high, 
cumulative dose of DOX, also showed protective effects of amifostine (Herman et al., 2000; 
Nazeyrollas et al., 2003). Amifostin dose was in range from 7 to 200 mg/kg, depending on 
the experimental model employed. However, concerning the methodology used, it was not 
possible to give some solid evidence about the amifostine molecular mechanism of action. 
We supposed that amifostine protected cardiomyocytes plasmalemma owing to its 
scavenging activity, and influenced the duration of action potential, especially the recovery 
phase and Ca2+ movement across the cellular membrane (Dragojevic-Simic et al., 2004). This 
might have contributed to the reduction of subsequent signalling pathways caused by DOX, 
since its detrimental effect eventually led to myofibrillar degeneration. Although there are 
some other opinions, our own results, as well as results obtained by other authors, support 
the statement that acute and chronic toxicity of DOX share the same mechanisms and, 
accordingly, chronic toxicity arises from repeated episodes of acute exposure, inducing 
cumulative damage (Dragojevic-Simic et al., 2011a; Dragojevic-Simic et al., 2004; Jensen,  
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1986; Luo et al., 1997; Pelikan et al., 1986). Thus, not only formation of highly reactive 
oxygen species, especially OH. , should be blamed for acute, as well as chronic DOX 
cardiotoxicity, but also their scavenging could be the main mechanisms of amifostine 
protection against both types of toxicities. According to Luo et al., (1997), reactive oxygen 
species, by inducing lipid peroxidation, after application of DOX produce cytotoxic 
aldehydes which result in inflamatory reactions (Luo et al., 1997). This eventually leads to 
increased synthesis of cytokines, infiltration of mononuclear cells and death of heart cells. In 
accordance with that, in our already described experiment (Dragojevic-Simic et al., 2004), 
the presence of mononuclear cells and fibroblasts was decreased in amifostine-protected rats 
compared with DOX-only treated group, and the necrotic cardiomyocytes were very rare. It 
has already been demonstrated that reactive oxygen species are increasingly produced by 
inflammatory cells in response to stimulation by cytokines such as TNF-, IL-1, IL-6 and IL-
17 and play an important role as messengers of the intracellular signaling pathways (Babbar 
& Casero, 2006; Jamaluddin et al., 2007). It was suggested that ROS, in turn, activate 
inflammatory cells that have part in the progression of inflammation. Therefore, targeting 
ROS may have a therapeutic value as a strategy to reduce the development of inflammation. 
It was already shown that amifostine, given in doses of 186 mg/kg per os, showed significant 
reduction of paw oedema in the carrageenan-induced paw inflammation in mice, 
comparable to that achieved by aspirin (Bhutia et al., 2010). Moreover, in our previous 
experiments amifostine reduced carrageenan-induced rat paw oedema achieving high 
degree of anti-inflammatory activity. Given in doses of 100, 200 and 300 mg/kg, ip 30 min 
before carrageenan challenge, it significantly reduced footpad swelling being the most 
effective in the highest dose tested (Dragojevic-Simic et al., 2011b). Therefore, anti-
inflammatory effects of amifostine can contribute to its protective effects in DOX-induced 
cardiotoxicity. On the other hand, in our previous experiments amifostine provided 
significant protective effects against early toxic changes in rat heart induced by single high 
doses of DOX (6 and 10 mg/kg iv) (Dobric et al., 1998; Dragojevic-Simic et al., 2007; 
Dragojevic-Simic et al., 2011a). Amifostine (300 mg/kg ip, 30 min, before DOX) successfully 
prevented significantly increased activity of CK, AST, LDH and -HBDH enzymes, as well 
as malondialdehyde (MDA) level in the serum of animals treated with DOX in a dose of 
6mg/kg. In a similar experimental model Bolaman et al (2005) showed that MDA level was 
lower, and glutathione and catalase levels were higher in the hearts of amifostine-pretreated 
group of animals comparing to unprotected rats (Bolaman et al., 2005). In our experiment 
(Dragojevic-Simic et al., 2011a) the application of amifostine in rats treated with DOX dose 
of 10 mg/kg reduced MCD score to the value obtained in the group of rats treated with 6 
mg/kg of DOX, only. The ultrastructural analysis (UA) showed that pretreatment with 
amifostine in rats which received 6mg/kg of DOX successfully protected sarcolemma of 
cardiomyocytes, while the mitochondria damage in the protected group was far less 
prominent. Capillaries were less morphologically changed and apoptosis of endothelial cells 
was extremely rare in comparison with non-treated animals. The UA of the rat heart 48 
hours after administration of 6mg/kg of DOX in this experiment revealed cardiomyocyte 
alterations described as oncosis. This is in accordance with the results of other authors, who 
also showed that the earliest and most often changes in the rat heart after application of high 
doses of DOX were cellular oedema and swelling of the mitochondria in cardiomyocytes. 
On the other hand, low-dose DOX exposure induced apoptosis of  these cells (L'Ecuyer et al., 
2004; Olson, H. M. & Capen, 1977; Simunek et al., 2009; Zhang, Y. W. et al., 2009). Our 
findings concerning prominent protection of mitochondria with amifostine are in line with  
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widely accepted hypothesis that mitochondria are a primary target of DOX-induced 
oxidative stress (Berthiaume & Wallace, 2007; Grdina et al., 2002). It is also known that 
amifostine is negative charged thiol and this protector accumulates within the mitochondria 
and around DNA, explaining higher protective amifostine potential for them than neutral or 
positive charged thiols, especially since some studies using perfused rat hearts showed that 
DOX is localized primarilly to the nucleus and mitochondria of the cell (Berthiaume & 
Wallace, 2007). It was also shown that both amifostine and WR-1065 significantly reduced 
DOX-induced heart cell toxicity, measured by ATP content normalised to total cellular 
protein (Marzatico et al., 2000). This finding can also be explained by effective protection of 
mitochondria, as in our study, since oxidative phosphorylation is one of the functions of this 
organelae which provides a substantial portion of the ATP needed to meet energy demands 
in the heart. On the other hand, as already mentioned, several lines of evidence suggest that 
amifostine is presumably modified into WR-1065 by membrane-bound alkaline 
phosphatase, highly expressed in the endothelium, It quickly penetrates into cells, where it 
acts as free-radicals scavengers and protects cells from oxidative damage (Calabro-Jones et 
al., 1988; Dragojevic-Simic & Dobric, 1996; Smoluk et al., 1988; Utley et al., 1984; Yuhas, 
1980). Potent protective effects of amifostine pretreatment in the model of 
lipopolysaccharide (LPS) -induced lung injury in vivo and attenuation of pulmonary 
endothelial cell barrier dysfunction in vitro via attenuation of oxidative stress, inhibition of 
redox-sensitive MAP kinases, NF-κB inflammatory cascade, as well as attenuation of LPS-
induced cytosceletal remodeling and disruption of endothelial cell adhesions leading to the 
preservation of endothelial cell monolayer integrity were shown (Fu et al., 2009). On the 
other hand, marked elevatation of the expression of antioxidant gene manganese superoxide 
dismutase (MnSOD) in human microvascular endothelial cells following their exposure to a 
WR-1065 can result in elevated resistance to the cytotoxic effects of ionizing radiation. 
Namely, MnSOD is nuclear-encoded mitochondrial enzyme that scavenges O2
.-  in 
mitochondrial matrix, and has been shown to be highly protective against radiation-induced 
ROS (Murley et al., 2006). Based on the current data, we speculate that succesful amifostine 
protection of DOX-induced damage of heart capillaries, whose endothelium, as a rich source 
of oxidants, contributes a lot to the oxidant-rich environment at that locus in this model 
(Dobric et al., 1998; Dragojevic-Simic et al., 2007; Dragojevic-Simic et al., 2011a), may be 
mediated by its antioxidant properties resulting in downregulation of oxidative stress and 
redox-sensitive signalling cascades. It is obvious that mechanisms of amifostine protection 
against DOX-induced cardiotoxicity, different from traditionally emphasized "scavenging 
free radicals" are also involved in amifostine-induced cardioprotection. Therefore, not only 
further preclinical and clinical studies are needed in order to implement amifostine in 
everyday oncological practice more succesfully, but also they should enable further progress 
in elucidation of DOX cardiotoxicity mechanisms, which represent a perpetual enigma.  
5. Fullerenol C60(OH)24 
With discovery of fullerene, 25 years ago (Kroto et al., 1985), started new era in chemical 
sciences. Fullerene, the third carbon allotrope, is a classical engineered material with the 
potential application in biomedicine. Spherical fullerene C60, known as backyball, is the 
most representative member of the fullerene family. With the shape of an icosahedron, 
containing 12 pentagons and 20 hexagons (Hirsch & Brettreich, 2005; Kratschmer et al., 
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1990), C60 become symbol of symmetry in chemistry and important member of 
nanomaterials family (Figure. 4). Unique physical and chemical properties, made backyball 
to quickly find its application in the material science, electronics and nanotechnology.  
The biological activities of fullerenes are considerably influenced by their chemical 
modifications and light treatment. The most relevant feature of fullerene C60 is the ability to 
act as a free radical scavenges. Properties attributed to the delocalized π double bond system 
of fullerene cage allow C60 to quench various free radicals more efficiently than conventional 
antioxidants. The chemical modification of fullerenes by adding the OH groups to their 
carbon surface yields a variety of polyhydroxylated structures C60(OH)x exhibiting different 
degrees of solubility and antioxidant activity in the aqueous environment (Xing et al., 2004; 
Zhang, Jian-Min et al., 2004). Polyhydroxylated derivate of fullerene - fullerenol (C60(OH)24) 
was synthesized in alkaline media by complete substitution of bromine atoms of C60Br24, 
with hydroxyl groups (Figure. 5.). New polyhydroxylated derivate completely maintains 
symmetry of parent C60 molecule(Djordjevic et al., 2005). Combination of the moderate 
electron affinity of fullerenol and their allylic hydroxyl functional groups makes fullerenol a 
suitable candidate for water-soluble antioxidants in biological systems. 
 
Fig. 4. Schematic representations of C60. (A) ball and stick model, (B) space filling model, (C) 
VB formula, (D) Schlegel diagram with numbering of the C-atoms (Hirsch & Brettreich, 
2005). 
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Fig. 5. Molecular structure of fullerenol 
Fullerenol C60(OH)24 exhibited antioxidative activity in nanomolar concentrations in dose 
dependent manner against stable 2,2-diphenyl-1-picrylhydrzyl (DPPH) radical and 
hydroxyl radical (OH) during the Fenton reaction using electron spin resonance (ESR) 
spectroscopy. Higher concentrations of fullerenol (0.71 – 0.88 mmol/L) stronger suppress 
production of hydroxyl radical than DPPH radical (Djordjevic et al., 2005). Authors 
suggested two possible mechanisms of antioxidative activity of fullerenol: (i) radical 
addition reaction of 2n ·OH radicals to remaining olefin double bonds of fullerenol core to 
yield C60(OH)24+2n·OH (n=1-12) and (ii) simultaneous hydrogen atom donation to DPPH 
and·OH including the formation of relatively stable fullerenol radical C60(OH)23O (Figure. 
6.) (Djordjevic et al., 2005). These mechanisms are not mutually excluded. Studies of 
antioxidative activity of fullerenol, imply that fullerenol C60(OH)24 has the ability to act both 
as an iron chelator and as a direct free radical scavenger. Study with hydroxyfullerene and 
metal salts demonstrated that fullerenols react rapidly and irreversibly with variety of metal 
salts within the pH range of 3.0-8.5, forming insoluble metal-hydroxifullerene cross-linked 
polymers (Anderson & Barron, 2005).  
Extensive in vivo studies on antioxidative protection of fullerenol against DOX induced 
toxicity were done. It was found that pretreatment with 100 mg/kg of fullerenol, succeed to 
abolish acute toxic effects on the heart, caused by single dose application of doxorubicin (10 
mg/kg i.p.)(Milic Torres et al., 2010). Previous studies have shown that application of 
doxorubicin causes damage of the heart and baroreceptors, which is indicated by reflex 
alterations (Rabelo et al., 2001). Results of this study showed that in DOX treated animals 
the reflexes were maintained, but their appearance was delayed, which implies the presence 
of some heart damage. Fullerenol in both applied doses (50 and 100 mg/kg i.p.) almost 
completely annulated this DOX induced disturbance and the time for appearance of 
adrenaline-induced reflex bradicardia in ECG record was in the level of control values. The 
most intensive cardiac histopathological changes, induced by DOX, were noticeable by light 
microscopy on the 14th day after the treatment. Fullerenol applied as a pretreatment, in 
dosage of 100 mg/kg, exerted protection and sustained structural integrity of the cardiac 
cells in DOX treated animals (Figure. 7.). Fullerenol, applied alone, in dosage of 100 mg/kg 
caused mild vascular changes, which are likely to be reversible. Both applied dosages (50 
and 100 mg/kg) used as a pretreatment, maintained the majority of investigated parameters 
(biochemical and parameters of oxidative stress) in the level of control values.   
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Fig. 6. Hypothesized mechanisms of fullerenol antioxidant activity 
This indicates the protective effect of polyhydroxylated fullerene. Results of work Milic 
Torres et al., confirm the hypothesis and complete the previously conducted investigation 
that indicated that fullerenol possess high antioxidative and cytoprotective potential, 
without any recorded side effect. Considering mechanisms of DOX toxicity (predominantly 
based on free radical production), previous investigation and results obtained in our 
experiment, it can be concluded that protective role of fullerenol is established on its high 
antioxidative potential. Regarding to unique electrochemical features, fullerenol exerts its 
antioxidant effect acting as a free radical sponge and/or removing of free iron through 
formation of fullerenol-iron complex and therefore enable further reaction with cell 
damaging by ROS . 
Protection against acute doxorubicin-induced toxicity was confirmed on other examinated 
parameters red blood cells (Djorjdevic-Milic et al., 2009), liver (Milic Torres V. et al. 
unpublished results), kidneys, lungs, and testicles, caused by administration of DOX in 
healthy Wistar rats (Srdjenovic et al., 2010).  
Injac et al., evaluated protective effect of C60(OH)24 on acute tissue oxidative injury mediated 
by single application of doxorubicin (8 mg/kg, i.p.) on female Sprague-Dawley rats with 
chemically induced mammary carcinomas. In this study, ultrastructural analysis of  
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Fig. 7. Histological section of the heart (HE, 40x): A) control group – no histological lesions 
found; B) group treated with doxorubicin – appearance of numerous vacuoles, total 
degeneration of normal tissue structure C) group treated with 50mg/kg of fullerenol 30 min. 
prior doxorubicin – focal hemorraghia, total degeneration of myocytes ; D) group treated 
with 100mg/kg of fullerenol 30 min (Milic Torres et al., 2010). 
www.intechopen.com
Doxorubicin-Induced Oxidative Injury  
of Cardiomyocytes – Do We Have Right Strategies for Prevention? 
 
111 
   
Fig. 8. Mitochondria showing (A) normal morphology, the double membrane envelope and 
lamellar cristae in the control rats; (B) irregular shape with lucent matrix and disorganised 
cristae in the Dox rats; and (C) amorphous material and rare disintegrated cristae in the 
Dox/Full rats (Injac, R. et al., 2008a).  
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ventricular tissues showed marked myocardial damage upon doxorubicin treatment. 
Ultrastructural analysis of the heart tissue from rats treated with doxorubicin and fullerenol 
indicated that hearts of the animals were protected from doxorubin-induced subcellular 
damage (Figure. 8.). Again, it was confirmed oxidative nature of cardiac injury caused by 
anthracycline application (elevated parameters of oxidative stress - SOD, MDA, GST, GSH, 
GR and TAS) and antioxidative capability of fullerenol, which maintain all examinated 
parameters at the basal level, when is applied as pretreatment to doxorubicin (Injac, R. et al., 
2008a) 
Protective effects of fullerenol C60(OH)24 on Wistar rats with colorectal carcinoma (chronic 
regimen of DOX administration – 1.5mg/kg/week, for 3 weeks)) was assessed by the same 
research group. They findings confirmed cardioprotective role of fullerenol, without 
modulation of antitumor activity of the drug. The myocardial lesions caused by doxorubicin 
administration were significantly reduced in animals received fullerenol. Functional and 
biochemical examination of the heart were in concordance with pathohystological findings. 
Moreover, fullerene exhibit significantly higher degree of protection over the well known 
antioxidant – vitamin C, which was used as a positive control (Injac, R. et al., 2009).  
In favour to C60(OH)24 cardioprotectivity are going biodistribution studies of fullerene. Ji et 
al, found that the high concentration of the 125I-C60(OH)x in the heart was able to detect even 
three days after the administration (Ji et al., 2006) 
 
Fig. 9. Static scintigraphy analysis of dog: 1. heart activity after 1 hour; 2. liver activity after 1 
hour; 3. kidney and urinary bladder activities after 24 hours; 4. kidney and urinary bladder 
activities after 21 hours; 5. liver, kidneys and urinary bladder activities after 24h; 6. salivary 
glands activity after 24 hours; 7. heart activity after 24 hours 
Dynamic scintigraphy of the domestic dog, using 99mTcO4-tagged fullerenol 
([99mTc(CO)3(H2O)3]-C60(OH)22-24)  discovered its presence in the heart, liver and spleen. 
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After administration of radiopharmaceutical, activity was first recorded on the heart, 
followed by liver and spleen (Figure. 9.). However, thirty minutes after, activity in all three 
organs was stabilized. The static scintigraphy reveals activity in the heart, liver, spleen and 
intestine after 1h, in salivary glands after 4 h and after 21 h the activity was detected in 
kidneys, urinary bladder and urinary tract. After 24 hours, the activity was detected in liver, 
spleen, kidneys and urinary bladder (Figure. 9.). These results suggest liver and urinary 
elimination mechanisms of tested xenobiotic with clearance of >24h (Djordjević et al., 2010). 
Special interest for further investigation with fullerenol will be focused on its 
radioprotective activity in animal models, and on cardioprotective effects in doxorubicin-
induced cardiotoxicity. However, main drawback for application of fullerenol as a system 
tissue protector is its water solubility of 0.44 mg/l, which is not satisfactory (Injac, Rade et 
al., 2008b). Enchasing of solubility using surfactants (Milic Torres et al., 2011) or co-solvent 
(Injac, Rade et al., 2008b), can facilitate fullerenol parenteral or oral application. 
All these findings suggests that fullerenol C60(OH)24 have all properties of ideal 
cardioprotector against doxorubicin-induced cardiotoxicity – selectivity, ROS scavenger, 
iron chelator, low toxicity and no modulatory effect on antitumor  activity of anthracyclines. 
Further ex vivo experiments as well as improvement of pharmaceutical formulations of the 
fullerene are strongly needed. 
6. Natural products 
The production of free radicals as a by product of DOX metabolism is the cardiotoxic 
mechanism with earliest recognition and widest attention. Therefore, searching for ideal 
protection against free radical injury was and still is a big scientific challenge. Application of 
natural antioxidants was first and logical path in this journey.  
Numerous studies about protective effects of vitamin E against DOX-induced cardiotoxicity 
are quite controversial. Vitamin E: Protective effect vitamin E exerted against chronic DOX-
induced toxicity on rabbit model when is administrated in high dosage as a pretreatment 
(170 mg/kg)(Van Vleet & Ferrans, 1980) or given in combination with vitamin A, reducing 
myocardial damage for 30% and maintained heart contractility (Milei et al., 1986). 
Berthiaume and co-workers found that alpha-tocopherol supplemented diet result in 
significant enrichment of cardiac mitochondrial membranes with vitamin E and diminished 
content of oxidized cardiac proteins associated with DOX treatment. However, vitamin E 
supplemented diet failed to protect against mitochondrial dysfunction and cardiac 
histopathology. These findings suggested that tocopherol enrichment is not sufficient to 
protect cardiac mitochondrial membranes from DOX induced toxicity (Berthiaume et al., 
2005). In doxorubicin treated leukemic mice, free alpha tocopherol and tocopherol acetate 
cause potentiation of doxorubicin toxicity (Alberts et al., 1978). High dosage of vitamin E 
failed to protect the heart tissue of the rabbits received cumulative dose of 400 mg/sq m of 
DOX in chronic regimen. Notwithstanding, coadministration of vitamin E result in 
increasing life span (Breed et al., 1980). Vitamin E administrated in high dosage of 5000 
IU/day, in chronic regimen (17 days) just cause mild amelioration of DOX-induced 
cardiotoxicity in miniature swine(Herman & Ferrans, 1983). Alpha-tocopherol in oral dose 
of 2g/m2 applied daily enriches human serum with vitamin E from six to eight fold. 
However, coadministrated with DOX in cumulative dose level of 550 mg/m2 did not offered  
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substantial protection against congestive heart failure which appeared in tested human 
individuals (Legha et al., 1982b).Vitamin A: Pretreatment of rats in dosage of 25 IU/kg of 
vitamin A, two days before single dose administration of DOX (10mg/kg i.v.) substantially 
reduced the peroxidative damage of the heart lipids and proteins, and markedly lowered 
serum values of lactate dehydrogenase and creatine kinase. This applied regimen sustained 
structural integration of the heart and prolonged life span of tested animals pointing on 
protective role of vitamin A in DOX-induced cardiotoxicity (Tesoriere et al., 1994). Lu and 
co-workers suggests strong cardioprotective activity of beta-carotene, when is given as a 
pretreatment to DOX (Lu et al., 1996). L-carnitine appared to be cardioprotective in 
doxorubicin treated rats, due to improved cardiac energy metabolism and reduced lipid 
peroxidation (Luo et al., 1999). Pretreatment of isolated rat cardiac myocytes with L-
carnitine (200 g/ml) found to inhibit the doxorubicin induced sphingomyelin hydrolysis, 
ceramide generation and cell death in dose dependent manner (Andrieu-Abadie et al., 1999). 
Aplication of alpha-lipoic acid exerted cytoprotective activity against free radical injury 
induced by doxorubicin. It succeed to maintain biochemical parameters of oxidative stress 
of treated rats and to sustain structural integrity of the rat heart as well (Al-Majed et al., 
2002; Balachandar et al., 2003). Extensive review was made about coenzyme Q-10 in 
prevention of anthracycline-induced cardiotoxicity. Both, preclinical and clinical studies 
suggest its cardioprotective role without compromising antitumor activity of the DOX. 
Applied in daily dose range between 50 and 120 mg/day coenzyme Q-10 can ameliorate 
majority of side effects associated with anthracycline administration including heart failure 
(Conklin, 2005). Wistar rats were treated with doxorubicin (4mg/kg) and lycopene (5 mg/kg 
body weight a day) during seven week period. Morphologic examination revealed that 
doxorubicin-induced myocyte damage was significantly suppressed in rats treated with 
lycopene. Lycopene supplementation provided myocyte protection without preventing 
interstitial collagen accumulation increase, although cardiac dysfunction was not preserved 
(Anjos Ferreira et al., 2007). Lycopene may reduce or prevent the side effects of 
chemotherapy due its antioxidative and anti-inflammatory properties (Sahin et al., 2010). 
Probucol, a lipid-lowering agent with known antioxidative properties, coadministrated with 
DOX to the male Sprague-Dawley in dosage of 10 mg/kg during four weeks with 
pretreatment of additional two weeks, completely abolished increase in oxidative stress, 
glutathione peroxidase (GSH-Px) inactivation and Mn dependent SOD downregulation 
during DOX cardiomyopathy. Li et al. suggested that rather oxidative stress mediated 
changes at the enzyme protein level playing role in toxicity of DOX than downregulation of 
the GSH-Px gene transcription or translation (Li, T. et al., 2000; Li, T. & Singal, 2000). Low 
molecular weight heparin (LMWH) administration to DOX-induced rats prevented the rise in 
serum and tissue levels of LDH, aminotransferases and ALP, while these parameters were 
significantly elevated in the DOX group in comparison with the control group. 
Cardiotoxicity indicated by rise in serum CPK in the DOX group was attenuated by LMWH 
treatment. LMWH decreased the cardiac lipid peroxidation induced by DOX. Histologic 
examination revealed that the DOX-induced deleterious changes in the heart were offset by 
LMWH treatment (Deepa & Varalakshmi, 2003). Chlopcikova and co-workers were tested 
chemoprotective effects of caffeic (CA), chlorogenic (CHA) and rosmarinic (RA) acids the 
toxicity of doxorubicin in neonatal rat cardiomyocytes and the iron-dependent DOX 
induced lipid peroxidation of heart membranes, mitochondria and microsomes. The test 
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compounds protected cardiomyocytes against DOX induced oxidative stress (RA > CHA > 
or = CA) on all monitored parameters. Substantial preservation of monolayer integrity of the 
cardiomyocytes by test compounds was also found microscopically. All the acids were more 
effective in the assays used than dexrazoxan. RA showed the most effective cytoprotectivity. 
All the acids significantly reduced the iron-dependent DOX induced lipid peroxidation of 
heart membranes, although CHA from the all tested compounds was found to be the most 
effective (Chlopcikova et al., 2004). Efficacy of the aqueous extract of the Centella asiatica was 
evaluated on the mitochondrial enzymes; mitochondrial antioxidant status in adriamycin 
induced myocardial injury. Pretreatment of the Wistar rats during three weeks with 
aqueous extract of Centella asiatica (orally 200 mg/kg body wt/ day) followed by co-
treatment with DOX (2.5 mg/kg, i.p. two weeks) effectively counteracted the alterations in 
mitochondrial enzymes and mitochondrial defence system. In addition, transmission 
electron microscopy study confirms the restoration of cellular normalcy and accredits the 
cytoprotective role of Centella asiatica against adriamycin induced myocardial injury. 
Results of Gnanapragasam  et al. suggest  that the aqueous extract of Centella asiatica not 
only possesses antioxidant properties but it may also reduce the extent of mitochondrial 
damage (Gnanapragasam et al., 2007). Oral administration of Aloe barbadensis gel – aloe vera 
(100 and 200 mg/kg), to the albino rats during 10 days, produced a significant protection 
against cardiotoxicity induced by DOX (single dose 7.5 mg/kg i.v.). Aloe vera gel kept 
serum levels of LDH, CPK, cardiac lipid peroxides, tissue catalase and tissue SOD along 
with the blood and tissue GSH on the basal values. The results revealed that aloe vera gel 
exhibit a dose dependent protection against DOX induced cardiotoxicity (Kaithwas et al., 
2011). Effect of methanolic extract of fruits of Piper longum (PLM) on the biochemical 
changes, tissue peroxidative damage and abnormal antioxidant levels in DOX induced 
cardiotoxicity in Wistar rats was investigated by Wakade and co-workers. Piper longum 
extract was administered to the Wistar rats in two different doses, by gastric gavage (250 
mg/kg and 500 mg/kg) during three weeks followed by unidose of DOX (15 mg/kg, i.p.) at 
the 21st day. Activities of myocardial antioxidant enzymes (CAT, SOD, GSH-Px, GR and 
GSSG) were significantly lowered due to cardiotoxicity in rats administered with DOX. PLM 
pretreatment maintain of these endogenous antioxidants on the level of control. Structural 
examination of the heart revealed degenerative changes and cellular infiltrations in rats 
administered with DOX and pretreatment with PLM reduced the intensity of such lesions. 
The results indicate that PLM administration offers significant protection against DOX 
induced oxidative stress and reduces the cardiotoxicity of the administrated antineoplastic 
drug (Wakade et al., 2008). Flavonoid scavenging activity of propolis has been investigated 
against oxidative injury of the heart, induced by single dose administration of DOX (20 
mg/kg, i.p.). Pretreatment of rats with propolis extract, given per os (100 mg/kg/day) 
during four days prior to DXR injection, substantially reduced the peroxidative damage of 
the heart mitochondria. It was evident significant reducing both mitochondrial MDA 
formation and production of superoxide anion. These data are demonstrated potent role of 
propolis extract counteracting doxorubicin caused cardiotoxicity (Alyane et al., 2008). Strong 
cardioprotection based on ROS scavenging activity against acute DOX induced toxicity was 
exhibited by: hesperetin – hypocholesterolemic citrus flavonoid (50 and 100 mg/kg) (Trivedi 
et al., 2011); melatonin (2x 5mg/kg) (Aydemir et al., 2010); resveratrol (10 mg/kg)(Danz et al., 
2009; Olukman et al., 2009; Tatlidede et al., 2009); procyanidins from grape seeds (15 
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mg/kg)(Li, W. et al., 2009); silymarin, flavonolignans extracted from Silybum marianum (50 
mg/kg) (El-Shitany et al., 2008) and salvianolic acid from Salvia miltiorrhiza (3 x 40mg/kg 
before DOX)(Jiang et al., 2008). 
It is obvious that diverse natural products have powerful ability to counteract the toxicity of 
doxorubicin and other anthracycline antibiotics. Unfortunately, the results from the studies 
conducted so far, are from pre clinical phase, rarely some of them reach clinical trials, and 
none is defined as a commercial protector. Use of natural antioxidants, against DOX 
induced cardiotoxicity, according to our knowledge, are recommended by a physician as a 
supplement to the treatment protocols in oncology. There are no scientific and clear 
evidences of their beneficial effects in large cohorts. 
7. Conclusion 
Cardiac complications induced by doxorubicin therapy are of considerable importance 
today as when was appeared 30 years ago. Furthermore, the number of the patients 
surviving cancer and chemotherapy is bigger nowdays and appearance of subclinical 
cardiac dysfunction is even more frequent. Mechanisms underlying cardiotoxicity of DOX 
are complex. In spite of multitude hypothesises involving gene expression changes, 
activation of ubiquitin-proteasome system, cell death as well as innate immunity activation, 
oxidative injury of the heart and alteration in iron homeostasis most likely to have primary 
role in cardiotoxicity developed by doxorubicin. No single drug will be able to prevent 
cardiotoxicity. Therefore, more clinical studies are needed to elucidate the mechanism and 
develop strategies in prevention against DOX-induced cardiotoxicity. 
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